APP Pharmaceuticals, a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals, has obtained FDA clearance for marketing preservative-free Heparin Lock Flush Solution, USP in two dosage strengths, 10 USP Units/1ml and 100 USP Units/1ml in single vials.
APP Pharmaceuticals said that its heparin products benefit from carefully designed packaging and labels, which helps in preventing medical errors by helping physicians and clinicians deliver the right dose to the right patient.
APP Pharmaceuticals claimed that it is a consistent supplier of heparin to the market place and this approval provides healthcare professionals with the only preservative-free Heparin Lock Flush Solution in a single dose vial.
John Ducker, president and CEO of APP Pharmaceuticals, said: “The FDA clearance to market a preservative-free Heparin Lock Flush Solution provides healthcare professionals with a safer alternative to maintain the patency of intravenous injection devices used in neonates and pediatric patients. This approval further expands our comprehensive heparin product line.”